Primary navigation

    Arcapta

    Drug - Arcapta (indacaterol) [Novartis]

    June 2012

    Therapeutic area - COPD

    Approval criteria

    • Patient has a diagnosis of COPD AND
    • Patient has tried and failed 2 of the following 3 drugs used for maintenance treatment of COPD: Serevent, Foradil, Spiriva

    Quantity limit

    Quantity Limit = 30

    Background information

    ARCAPTA NEOHALER is a long-acting beta2-adrenergic agonist indicated for: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top